Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Sahar F. Bannoura, Husain Yar Khan, Asfar S. Azmi
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Next-generation therapies for pancreatic cancer
Conor Buckley, Eileen M. O’Reilly
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 1-3, pp. 55-72
Open Access | Times Cited: 12
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers
Snigdha Banerjee, Affan A. Ansari, Sunil P. Upadhyay, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 395-395
Open Access | Times Cited: 7
Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer
Mohd Rais Mustafa, Kashif Abbas, Mudassir Alam, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 6
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics
Ioannis A. Voutsadakis
Critical Reviews in Oncology/Hematology (2023) Vol. 186, pp. 103987-103987
Closed Access | Times Cited: 15
Graphene oxide nanoarchitectures in cancer therapy: Drug and gene delivery, phototherapy, immunotherapy, and vaccine development
Mohammad Saleh Sadeghi, Faezeh Hosseini Sangrizeh, Negar Jahani, et al.
Environmental Research (2023) Vol. 237, pp. 117027-117027
Closed Access | Times Cited: 14
Exploring the Therapeutic Potential of Focal Adhesion Kinase Inhibition in Overcoming Chemoresistance in Pancreatic Ductal Adenocarcinoma
Fabio Scianò, Francesca Terrana, Camilla Pecoraro, et al.
Future Medicinal Chemistry (2024) Vol. 16, Iss. 3, pp. 271-289
Closed Access | Times Cited: 5
Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance
Jameela Lokhandwala, Tracess Smalley, Timothy H. Tran
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy
Laura D'Alessio‐Sands, Joshua Gaynier, Victoria Michel‐Milian, et al.
Drug Development Research (2025) Vol. 86, Iss. 1
Closed Access
The Landmark Series: The Future of Pancreatic Cancer Clinical Trials
Yongwoo David Seo, Matthew H. G. Katz, Rebecca A. Snyder
Annals of Surgical Oncology (2025) Vol. 32, Iss. 4, pp. 2777-2785
Closed Access
Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future
Peiliang Dong, Jiating Ni, Xinyue Zheng, et al.
European Journal of Pharmacology (2025), pp. 177428-177428
Closed Access
The potential applications of peptide-loading complex in cancer treatment
Zhidu Song, Ying Tao, Jiaxin You
Frontiers in Immunology (2025) Vol. 16
Open Access
Deciphering of SOX9 Functions in Pancreatic Cancer Cells
К. Н. Кашкин, L. G. Kondratyeva, E. P. Kopantzev, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2652-2652
Open Access
Combined Omipalisib and MAPK Inhibition Suppress PDAC Growth
Bailey A. Bye, Jarrid Jack, Alexandra Pierce, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1152-1152
Open Access
Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways
Hnin Ei Ei Khine, Utid Suriya, Thanyada Rungrotmongkol, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors
Aslamuzzaman Kazi, Alok Ranjan, Vasantha Kumar M.V., et al.
Cancer Research Communications (2023) Vol. 3, Iss. 12, pp. 2623-2639
Open Access | Times Cited: 12
A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation
Su He Wang, Zhengyi Cao, Mohammad Farazuddin, et al.
Cancer Gene Therapy (2024)
Closed Access | Times Cited: 4
Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in Therapeutic Implication of Cancers
Snigdha Banerjee, Affan A. Ansari, Sunil P. Upadhyay, et al.
(2024)
Open Access | Times Cited: 4
Inhibition of GTPase KRAS G12D : a review of patent literature
Yuhang Li, Le Yang, Xiaoran Li, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 8, pp. 701-721
Closed Access | Times Cited: 4
Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues
Ioannis A. Voutsadakis, Antonia Digklia
Chinese Clinical Oncology (2023) Vol. 12, Iss. 1, pp. 2-2
Open Access | Times Cited: 10
Advancements in Systemic Therapy for Pancreatic Cancer
Timothy J. Brown, Kim A. Reiss, Mark H. O’Hara
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Closed Access | Times Cited: 10
KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
Enrico Gurreri, Giannicola Genovese, Luigi Perelli, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9313-9313
Open Access | Times Cited: 9
Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)
Joshua Zhang, Lily Darman, Mohammad Rashedul Hassan, et al.
Oncology Reports (2023) Vol. 50, Iss. 5
Open Access | Times Cited: 9
Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-d]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRASG12D Inhibitors
Xuanzheng Xiao, Juanjuan Feng, Jing Ma, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 22, pp. 15524-15549
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top